Deutsche Bank’s Achillion Pharmaceuticals ACHN Stock Holding History

Deutsche Bank’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-447	Closed	-$4K	–	5430
2015 Q4	$4K	Hold	447	–	–	﹤0.01%	5094
2015 Q3	$3K	Sell	447 -93	-17%	-$758	﹤0.01%	5091
2015 Q2	$4K	Sell	540 -460	-46%	-$4.35K	﹤0.01%	5185
2015 Q1	$9K	Buy	1,000 +452	+82%	+$5.64K	﹤0.01%	4818
2014 Q4	$6K	Buy	+548	New	+$6.69K	﹤0.01%	5852
2013 Q3	–	Sell	-2,772	Closed	-$6K	–	5824
2013 Q2	$6K	Buy	+2,772	New	+$21.2K	﹤0.01%	5009

Deutsche Bank's ACHN Position: Q1 2020 in Review

Deutsche Bank sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 45,651 shares — an estimated $275K sold.

Deutsche Bank first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $15.3M in Q4 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

Deutsche Bank reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Deutsche Bank sold 45,651 Achillion Pharmaceuticals shares in Q1 2020, an estimated $275K.
Deutsche Bank first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
Deutsche Bank's Achillion Pharmaceuticals position peaked at $15.3M in Q4 2015.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Deutsche Bank's 13F filing for Q1 2020, filed 14 May 2020.